Trial Profile
An open label, randomised, three arm, single dose, multicentre, parallel group study in healthy subjects to compare the pharmacokinetics of subcutaneous mepolizumab when delivered as a liquid drug product in a safety syringe or an auto injector with a reconstituted lyophilised drug product from a vial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma
- Focus Pharmacokinetics; Registrational
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 04 Jun 2019 According to a GlaxoSmithKline media release, data from this trial supported the positive opinion of CHMP recommending two new methods for administering Nucala (mepolizumab) to patients with severe eosinophilic asthma: a pre-filled pen and a pre-filled safety syringe, to be taken once every four weeks.
- 28 Mar 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 25 Aug 2017 Status changed from active, no longer recruiting to completed.